Cladis Investment Advisory’s iShares Biotechnology ETF IBB Stock Holding History

Cladis Investment Advisory’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$984K	Sell	5,175 -100	-2%	-$17.2K	0.46%	63
2026 Q1	$891K	Sell	5,275 -100	-2%	-$17.1K	0.49%	67
2025 Q4	$907K	Sell	5,375 -50	-0.9%	-$8.12K	0.5%	64
2025 Q3	$783K	Sell	5,425 -285	-5%	-$38.9K	0.45%	67
2025 Q2	$722K	Hold	5,710	–	–	0.45%	67
2025 Q1	$730K	Buy	5,710 +570	+11%	+$77.3K	0.53%	59
2024 Q4	$680K	Buy	5,140 +840	+20%	+$118K	0.48%	64
2024 Q3	$626K	Buy	4,300 +1,265	+42%	+$183K	0.43%	68
2024 Q2	$417K	Buy	3,035 +115	+4%	+$15.4K	0.3%	88
2024 Q1	$401K	Buy	+2,920	New	+$399K	0.29%	90

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.9% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Cladis Investment Advisory's IBB Position: Q2 2026 in Review

Cladis Investment Advisory reduced its iShares Biotechnology ETF (IBB) stake by 1.9% in Q2 2026, selling an estimated $17.2K and leaving 5,175 shares worth $984K. The position accounts for 0.46% of the portfolio, ranked #63.

Cladis Investment Advisory first reported a position in IBB in Q1 2024 and has held it in 10 quarters since. 960 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Cladis Investment Advisory held 5,175 shares of iShares Biotechnology ETF worth $984K as of Q2 2026.
Cladis Investment Advisory sold 100 iShares Biotechnology ETF shares in Q2 2026, an estimated $17.2K.
iShares Biotechnology ETF made up 0.46% of Cladis Investment Advisory's portfolio in Q2 2026, its #63 holding.
Cladis Investment Advisory first reported a position in iShares Biotechnology ETF in Q1 2024 and has held it in 10 quarters since.
960 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Cladis Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.